Literature DB >> 28141920

Face Transplantation: Partial Graft Loss of the First Case 10 Years Later.

E Morelon1,2, P Petruzzo3,4, J Kanitakis5, S Dakpé6, O Thaunat1,2, V Dubois7, G Choukroun8, S Testelin6, J-M Dubernard3, L Badet3, B Devauchelle6.   

Abstract

Ten years after the first face transplantation, we report the partial loss of this graft. After two episodes of acute rejection (AR) occurred and completely reversed in the first posttransplantation year, at 90 months posttransplantation the patient developed de novo class II donor-specific antibodies, without clinical signs of AR. Some months later, she developed several skin rejection episodes treated with steroid pulses. Despite rapid clinical improvement, some months later the sentinel skin graft underwent necrosis. Microscopic examination showed intimal thickening, thrombosis of the pedicle vessel, and C4d deposits on the endothelium of some dermal vessels of the facial graft. Flow magnetic resonance imaging of the facial graft showed a decrease of the distal right facial artery flow. Three steroid pulses of 500 mg each, followed by intravenous immunoglobulins (2 g/kg), five sessions of plasmapheresis, and three cycles of bortezomib 1.3 mg/m2 , were administered. Despite rescue therapy with eculizumab, necrosis of the lips and the perioral area occurred, which led to surgical removal of the lower lip, labial commissures, and part of the right cheek in May 2015. In January 2016, the patient underwent conventional facial reconstruction because during the retransplantation evaluation a small-cell lung carcinoma was discovered, causing the patient's death in April 2016.
© 2017 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  clinical research/practice; rejection: antibody-mediated (ABMR); rejection: chronic; vascularized composite and reconstructive transplantation

Mesh:

Substances:

Year:  2017        PMID: 28141920     DOI: 10.1111/ajt.14218

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  12 in total

1.  Chronic rejection of human face allografts.

Authors:  Nicco Krezdorn; Christine G Lian; Michael Wells; Luccie Wo; Sotirios Tasigiorgos; Shuyun Xu; Thiago J Borges; Rayven M Frierson; Ewelina Stanek; Leonardo V Riella; Bohdan Pomahac; George F Murphy
Journal:  Am J Transplant       Date:  2018-11-10       Impact factor: 8.086

Review 2.  The decade of face transplant outcomes.

Authors:  Maria Siemionow
Journal:  J Mater Sci Mater Med       Date:  2017-03-16       Impact factor: 3.896

3.  Enhancing Face Transplant Outcomes: Fundamental Principles of Facial Allograft Revision.

Authors:  Gustave K Diep; Elie P Ramly; Allyson R Alfonso; Zoe P Berman; Eduardo D Rodriguez
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-08-17

Review 4.  Composite tissue allotransplantation: opportunities and challenges.

Authors:  Jasper Iske; Yeqi Nian; Ryoichi Maenosono; Max Maurer; Igor M Sauer; Stefan G Tullius
Journal:  Cell Mol Immunol       Date:  2019-03-06       Impact factor: 11.530

5.  Immunoregulatory and lipid presentation pathways are upregulated in human face transplant rejection.

Authors:  Thet Su Win; William J Crisler; Beatrice Dyring-Andersen; Rachel Lopdrup; Jessica E Teague; Qian Zhan; Victor Barrera; Shannan Ho Sui; Sotirios Tasigiorgos; Naoka Murakami; Anil Chandraker; Stefan G Tullius; Bohdan Pomahac; Leonardo V Riella; Rachael A Clark
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

6.  Absence of Rejection in a Facial Allograft Recipient with a Positive Flow Crossmatch 24 Months after Induction with Rabbit Anti-Thymocyte Globulin and Anti-CD20 Monoclonal Antibody.

Authors:  Bruce E Gelb; J Rodrigo Diaz-Siso; Natalie M Plana; Adam Jacoby; William J Rifkin; Kimberly S Khouri; Daniel J Ceradini; Eduardo D Rodriguez
Journal:  Case Rep Transplant       Date:  2018-05-20

7.  MMP3 Is a Non-invasive Biomarker of Rejection in Skin-Bearing Vascularized Composite Allotransplantation: A Multicenter Validation Study.

Authors:  Branislav Kollar; Audrey Uffing; Thiago J Borges; Andrey V Shubin; Bruno T Aoyama; Céline Dagot; Valentin Haug; Martin Kauke; Ali-Farid Safi; Simon G Talbot; Emmanuel Morelon; Stéphanie Dakpe; Bohdan Pomahac; Leonardo V Riella
Journal:  Front Immunol       Date:  2019-11-29       Impact factor: 7.561

Review 8.  Therapeutic application of T regulatory cells in composite tissue allotransplantation.

Authors:  Jeong-Hee Yang; Seok-Chan Eun
Journal:  J Transl Med       Date:  2017-10-26       Impact factor: 5.531

Review 9.  Costimulation Blockade in Vascularized Composite Allotransplantation.

Authors:  Dimitrios Giannis; Dimitrios Moris; Linda C Cendales
Journal:  Front Immunol       Date:  2020-09-17       Impact factor: 7.561

10.  Long-term outcome after hand and forearm transplantation - a retrospective study.

Authors:  Theresa Hautz; Franka Messner; Annemarie Weissenbacher; Hubert Hackl; Martin Kumnig; Marina Ninkovic; Valeria Berchtold; Johanna Krapf; Bettina G Zelger; Bernhard Zelger; Dolores Wolfram; Gerhard Pierer; Wolfgang N Löscher; Robert Zimmermann; Markus Gabl; Rohit Arora; Gerald Brandacher; Raimund Margreiter; Dietmar Öfner; Stefan Schneeberger
Journal:  Transpl Int       Date:  2020-11-10       Impact factor: 3.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.